Tempus AI Buys Personalis in $1.5B Deal to Advance Blood-Based Cancer Detection
The deal combines advanced cancer diagnostics with Tempus’ AI platform for improved surveillance.
/ 1648 items
#XY↓
Abivax Re-Engages Centerview as It Eyes Major Pharma Partnerships After $874M Raise
Abivax has resumed partnership talks with major pharma companies via Centerview Partners while preparing a potential independent U.S. launch of obefazimod.
Zentalis Pharmaceuticals Gets Outperform Rating from Mizuho on Azenosertib Potential
Analyst highlights 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib.
Kalaris Reinforces TH103’s Potential in Wet AMD Ahead of 2027 Catalyst
Kalaris reports 6-month follow-up data from 20 patients in TH103 Phase 1a trial. 29% of treatment-naïve patients remained injection-free for 6 months. Phase 1b/2 data expected H1 2027.
Intuitive Surgical Shares Plunge as Da Vinci Procedure Growth Slows Sharply
GLP-1 drugs and insurance uncertainty weigh on demand.
REGENXBIO Prices $100 Million Public Offering to Extend Cash Runway into 2028
Proceeds will support late-stage AAV gene therapy programs and extend cash runway to 2028.